Higher blood pressure predicts diabetes and enhances long-term risk of cardiovascular disease events in individuals with impaired glucose tolerance: Twenty-three-year follow-up of the Daqing diabetes prevention study.


Journal

Journal of diabetes
ISSN: 1753-0407
Titre abrégé: J Diabetes
Pays: Australia
ID NLM: 101504326

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 08 10 2018
revised: 15 11 2018
accepted: 04 12 2018
pubmed: 18 12 2018
medline: 18 12 2019
entrez: 18 12 2018
Statut: ppublish

Résumé

Hypertension is more prevalent in subjects with impaired glucose tolerance (IGT), but whether higher blood pressure per se or the mild hyperglycemia in combination with the hypertension enhanced the risk of cardiovascular disease (CVD) remains unclear. Five hundred and sixty-eight participants with IGT in the original Daqing diabetes prevention study, 297 with hypertension (HBP) and 271 without hypertension (NBP), were enrolled in 1986 and the intervention phase lasted for 6 years. In 2009, they were followed up to assess the outcomes of cardiovascular events (including stroke and myocardial infarction) and incidence of diabetes. Over 23 years, the incidence of diabetes was 93.9/1000 person-years in HBP and 72.2/1000 person-years in the NBP group, with an age- and sex-adjusted hazard ratio of 1.26 (95% confidence interval [CI], 1.04-1.54, P = 0.02). The yearly incidence of CVD events was 27.7/1000 person-years and 16.6/1000 person-years, indicating a 35% higher risk in HBP than in the NBP group (95% CI, 1.01-1.81; P = 0.04). Cox proportional hazard analysis showed that a 10-mm Hg increase of the baseline systolic blood pressure was associated with 9% increased risk of the development of diabetes (P = 0.02), together with a 7% higher risk of the CVD events (P = 0.02). Hypertension predicted diabetes and enhances long-term risk of CVD events in patients with IGT. An individualized strategy that targets hypertension as well as hyperglycemia is needed for diabetes and its cardiovascular complications. 背景: 高血压在糖耐量受损(impaired glucose tolerance,IGT)人群中更为普遍。而它对心血管疾病(CVD)的影响是来自高血压本身还是轻度高血糖与血压的共同作用尚不清楚。 方法: 1986年大庆糖尿病预防研究初始纳入IGT患者568例,分为IGT伴高血压组297例,IGT不伴高血压组271例。对IGT患者进行6年生活方式干预。随访至2009年评估两组的新发糖尿病和心血管事件(包括脑卒中和急性心肌梗死)发生率。 结果: 随访23年中,IGT伴高血压组和不伴高血压组的2型糖尿病发生率分别为93.9/千人/年和72.2/千人/年。校正年龄和性别影响后,IGT伴高血压组的糖尿病发病风险为非高血压组1.26倍[95%可信区间(CI),1.04-1.54,P = 0.02]。心血管事件的发生率在IGT伴高血压组为27.7/千人/年,不伴高血压组为16.6/千人/年,与不伴高血压组相比,IGT伴高血压组的发病风险增加35%(95% CI,1.01-1.81,P = 0.04]。COX比例风险分析显示基线收缩压每升高10 mmHg,糖尿病的发生风险增加9.0%(P = 0.02),同时心血管事件的发生风险增加7%(P = 0.02)。 结论: 在糖耐量受损人群中,高血压预测2型糖尿病的发生,并提高长期心血管事件的发生风险。个体化治疗策略应是降糖的同时还兼顾降压,以预防糖尿病及心血管并发症发生。.

Sections du résumé

BACKGROUND BACKGROUND
Hypertension is more prevalent in subjects with impaired glucose tolerance (IGT), but whether higher blood pressure per se or the mild hyperglycemia in combination with the hypertension enhanced the risk of cardiovascular disease (CVD) remains unclear.
METHODS METHODS
Five hundred and sixty-eight participants with IGT in the original Daqing diabetes prevention study, 297 with hypertension (HBP) and 271 without hypertension (NBP), were enrolled in 1986 and the intervention phase lasted for 6 years. In 2009, they were followed up to assess the outcomes of cardiovascular events (including stroke and myocardial infarction) and incidence of diabetes.
RESULTS RESULTS
Over 23 years, the incidence of diabetes was 93.9/1000 person-years in HBP and 72.2/1000 person-years in the NBP group, with an age- and sex-adjusted hazard ratio of 1.26 (95% confidence interval [CI], 1.04-1.54, P = 0.02). The yearly incidence of CVD events was 27.7/1000 person-years and 16.6/1000 person-years, indicating a 35% higher risk in HBP than in the NBP group (95% CI, 1.01-1.81; P = 0.04). Cox proportional hazard analysis showed that a 10-mm Hg increase of the baseline systolic blood pressure was associated with 9% increased risk of the development of diabetes (P = 0.02), together with a 7% higher risk of the CVD events (P = 0.02).
CONCLUSIONS CONCLUSIONS
Hypertension predicted diabetes and enhances long-term risk of CVD events in patients with IGT. An individualized strategy that targets hypertension as well as hyperglycemia is needed for diabetes and its cardiovascular complications.
背景: 高血压在糖耐量受损(impaired glucose tolerance,IGT)人群中更为普遍。而它对心血管疾病(CVD)的影响是来自高血压本身还是轻度高血糖与血压的共同作用尚不清楚。 方法: 1986年大庆糖尿病预防研究初始纳入IGT患者568例,分为IGT伴高血压组297例,IGT不伴高血压组271例。对IGT患者进行6年生活方式干预。随访至2009年评估两组的新发糖尿病和心血管事件(包括脑卒中和急性心肌梗死)发生率。 结果: 随访23年中,IGT伴高血压组和不伴高血压组的2型糖尿病发生率分别为93.9/千人/年和72.2/千人/年。校正年龄和性别影响后,IGT伴高血压组的糖尿病发病风险为非高血压组1.26倍[95%可信区间(CI),1.04-1.54,P = 0.02]。心血管事件的发生率在IGT伴高血压组为27.7/千人/年,不伴高血压组为16.6/千人/年,与不伴高血压组相比,IGT伴高血压组的发病风险增加35%(95% CI,1.01-1.81,P = 0.04]。COX比例风险分析显示基线收缩压每升高10 mmHg,糖尿病的发生风险增加9.0%(P = 0.02),同时心血管事件的发生风险增加7%(P = 0.02)。 结论: 在糖耐量受损人群中,高血压预测2型糖尿病的发生,并提高长期心血管事件的发生风险。个体化治疗策略应是降糖的同时还兼顾降压,以预防糖尿病及心血管并发症发生。.

Autres résumés

Type: Publisher (chi)
背景: 高血压在糖耐量受损(impaired glucose tolerance,IGT)人群中更为普遍。而它对心血管疾病(CVD)的影响是来自高血压本身还是轻度高血糖与血压的共同作用尚不清楚。 方法: 1986年大庆糖尿病预防研究初始纳入IGT患者568例,分为IGT伴高血压组297例,IGT不伴高血压组271例。对IGT患者进行6年生活方式干预。随访至2009年评估两组的新发糖尿病和心血管事件(包括脑卒中和急性心肌梗死)发生率。 结果: 随访23年中,IGT伴高血压组和不伴高血压组的2型糖尿病发生率分别为93.9/千人/年和72.2/千人/年。校正年龄和性别影响后,IGT伴高血压组的糖尿病发病风险为非高血压组1.26倍[95%可信区间(CI),1.04-1.54,P = 0.02]。心血管事件的发生率在IGT伴高血压组为27.7/千人/年,不伴高血压组为16.6/千人/年,与不伴高血压组相比,IGT伴高血压组的发病风险增加35%(95% CI,1.01-1.81,P = 0.04]。COX比例风险分析显示基线收缩压每升高10 mmHg,糖尿病的发生风险增加9.0%(P = 0.02),同时心血管事件的发生风险增加7%(P = 0.02)。 结论: 在糖耐量受损人群中,高血压预测2型糖尿病的发生,并提高长期心血管事件的发生风险。个体化治疗策略应是降糖的同时还兼顾降压,以预防糖尿病及心血管并发症发生。.

Identifiants

pubmed: 30556339
doi: 10.1111/1753-0407.12887
pmc: PMC6618010
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

593-598

Subventions

Organisme : National Center for Chronic Disease Prevention and Health Promotion through CDC/WHO Cooperative Agreement No. U58/CCU424123-01-02 and by the China-Japan Friendship Hospital

Informations de copyright

© 2018 The Authors. Journal of Diabetes published by John Wiley & Sons Australia, Ltd and Ruijin Hospital, Shanghai Jiaotong University School of Medicine.

Références

Diabetologia. 2011 Feb;54(2):300-7
pubmed: 21046360
Lancet Diabetes Endocrinol. 2014 Jun;2(6):474-80
pubmed: 24731674
BMC Med Res Methodol. 2011 Jun 22;11:96
pubmed: 21696598
BMJ. 2016 Nov 23;355:i5953
pubmed: 27881363
J Am Coll Cardiol. 2010 Mar 30;55(13):1310-7
pubmed: 20338491
Lancet. 1999 Aug 21;354(9179):617-21
pubmed: 10466661
Diabetes Care. 2002 Oct;25(10):1845-50
pubmed: 12351489
Stroke. 2006 Jun;37(6):1413-7
pubmed: 16627787
BMJ. 1991 Mar 2;302(6775):493-6
pubmed: 2012844
Diabetes Care. 2009 Nov;32 Suppl 2:S284-9
pubmed: 19875566
Annu Rev Public Health. 1999;20:145-57
pubmed: 10352854
Diabetologia. 1999 Aug;42(8):926-31
pubmed: 10491751
Lancet. 2008 May 24;371(9626):1783-9
pubmed: 18502303
Cerebrovasc Dis. 2013;36(4):283-9
pubmed: 24135458
J Diabetes. 2019 Jul;11(7):593-598
pubmed: 30556339
Lancet. 2010 Jul 10;376(9735):112-23
pubmed: 20561675
Diabetes Care. 1997 Apr;20(4):537-44
pubmed: 9096977
N Engl J Med. 2010 Mar 25;362(12):1090-101
pubmed: 20335585
J Clin Hypertens (Greenwich). 2014 Aug;16(8):551-3
pubmed: 25040331
JAMA. 2013 Sep 4;310(9):948-59
pubmed: 24002281
Am J Cardiol. 2011 Aug 2;108(3 Suppl):3B-24B
pubmed: 21802577
QJM. 2010 Jul;103(7):495-503
pubmed: 20430755

Auteurs

Xiaojue Li (X)

Center of Endocrinology and Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Jinping Wang (J)

Department of Cardiology, DaQing First Hospital, Da Qing, China.

Xiaoxia Shen (X)

Center of Endocrinology and Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Yali An (Y)

Center of Endocrinology and Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Qiuhong Gong (Q)

Center of Endocrinology and Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Hui Li (H)

Department of Cardiology, DaQing First Hospital, Da Qing, China.

Bo Zhang (B)

Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.

Ying Shuai (Y)

Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.

Yanyan Chen (Y)

Center of Endocrinology and Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Yinghua Hu (Y)

Department of Cardiology, DaQing First Hospital, Da Qing, China.

Guangwei Li (G)

Center of Endocrinology and Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH